phosphorylcholine has been researched along with Melanoma in 8 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 9.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 5.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| "We investigated PC3 prostate cancer, MCF-7 breast cancer and A375 melanoma cells, and determined that, consistent with previous studies, MRS-detectable levels of phosphocholine decreased significantly in all cell lines (to 63%, 50% and 18% of the control, respectively) following MEK inhibition with U0126." | 1.40 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. ( Lodi, A; Ronen, SM; Woods, SM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 2 |
| Xie, X | 1 |
| Wang, W | 1 |
| Jiang, S | 2 |
| Mei, W | 2 |
| Zhang, Y | 1 |
| Liu, S | 2 |
| Yu, X | 2 |
| Wang, X | 1 |
| Yan, X | 1 |
| Pegoraro, C | 1 |
| Cecchin, D | 1 |
| Gracia, LS | 1 |
| Warren, N | 1 |
| Madsen, J | 1 |
| Armes, SP | 1 |
| Lewis, A | 1 |
| Macneil, S | 1 |
| Battaglia, G | 1 |
| Lodi, A | 1 |
| Woods, SM | 1 |
| Ronen, SM | 1 |
| Teymouri, M | 1 |
| Farzaneh, H | 1 |
| Badiee, A | 1 |
| Golmohammadzadeh, S | 1 |
| Sadri, K | 1 |
| Jaafari, MR | 1 |
| Ernst, DS | 1 |
| Eisenhauer, E | 1 |
| Wainman, N | 1 |
| Davis, M | 1 |
| Lohmann, R | 1 |
| Baetz, T | 1 |
| Belanger, K | 1 |
| Smylie, M | 1 |
| Ragnarsson-Olding, B | 1 |
| Djureen-Mårtensson, E | 1 |
| Månsson-Brahme, E | 1 |
| Hansson, J | 1 |
| Barna, BP | 1 |
| James, K | 1 |
| Deodhar, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma[NCT00053781] | Phase 2 | 18 participants (Actual) | Interventional | 2003-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Melanoma
| Article | Year |
|---|---|
Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Chondrocalcinosis; Female; Humans; Liver Neoplasms; Lung | 2005 |
7 other studies available for phosphorylcholine and Melanoma
| Article | Year |
|---|---|
Choline phosphate lipid as an intra-crosslinker in liposomes for drug and antibody delivery under guard.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Lipids; Liposomes; Melanoma; Mice; Ph | 2022 |
Choline phosphate lipid insertion and rigidification of cell membranes for targeted cancer chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Doxorubicin; Drug Delivery Systems; | 2021 |
Enhanced drug delivery to melanoma cells using PMPC-PDPA polymersomes.
Topics: Antibiotics, Antineoplastic; Cell Membrane Permeability; Cells, Cultured; Doxorubicin; Drug Delivery | 2013 |
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Butadienes; Cell Line, Tumor; Glycolysis; Humans; M | 2014 |
Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Drug Delivery Syst | 2015 |
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neo | 2005 |
Activation of human monocyte tumoricidal activity by C-reactive protein.
Topics: Astrocytes; Astrocytoma; C-Reactive Protein; Carcinoma, Renal Cell; Cell Line; Cytotoxicity Tests, I | 1987 |